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Purpose: 99mTc-iminodiacetic acid (IDA) hepatobiliary imaging is usually quantified for hepatic
function on the entire liver or regions of interest (ROIs) in the liver. The authors presented a method to
estimate the hepatic extraction fraction (HEF) voxel-by-voxel from single-photon emission computed
tomography (SPECT)/CT with a 99mTc-labeled IDA agent of mebrofenin and evaluated the spatially
resolved HEF measurements with an independent physiological measurement.
Methods: Fourteen patients with intrahepatic cancers were treated with radiation therapy (RT) and
imaged by 99mTc-mebrofenin SPECT before and 1 month after RT. The dynamic SPECT volumes
were with a resolution of 3.9 × 3.9 × 2.5 mm3. Throughout the whole liver with approximate 50 000
voxels, voxelwise HEF quantifications were estimated and compared between using arterial input
function (AIF) from the heart and using vascular input function (VIF) from the spleen. The correlation
between mean of the HEFs over the nontumor liver tissue and the overall liver function measured by
Indocyanine green clearance half-time (T1/2) was assessed. Variation of the voxelwise estimation was
evaluated in ROIs drawn in relatively homogeneous regions of the livers. The authors also examined
effects of the time range parameter on the voxelwise HEF quantification.
Results: Mean of the HEFs over the liver estimated using AIF significantly correlated with the phys-
iological measurement T1/2 (r = 0.52, p = 0.0004), and the correlation was greatly improved by
using VIF (r = 0.79, p < 0.0001). The parameter of time range for the retention phase did not lead
to a significant difference in the means of the HEFs in the ROIs. Using VIF and a retention phase
time range of 7–30 min, the relative variation of the voxelwise HEF in the ROIs was 10% ± 6% of
respective mean HEF.
Conclusions: The voxelwise HEF derived from 99mTc-IDA SPECT by the deconvolution analysis is
feasible to assess the spatial distribution of hepatic function in the liver. © 2013 American Association
of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4816655]
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1. INTRODUCTION
Scintigraphy and single-photon emission computed tomog-
raphy (SPECT) with a 99mTc-labeled analog of iminodi-
acetic acid (IDA) is currently the only imaging-based hepa-
tocellular function test in clinical settings. The clinical value
of 99mTc-IDA SPECT has been demonstrated in diagnosis
of various hepatobiliary diseases including acute hepatitis,1
primary biliary cirrhosis,2 acute jaundice,3 and others.4–6
Recently, SPECT with a 99mTc-labeled IDA derivative of
mebrofenin has shown potential to assess liver function
change in response to radiation therapy (RT).7
Following an intravenous injection, 99mTc-IDA is loosely
bound to plasma proteins and carried to the liver. The IDA is
extracted by the hepatocyte through an organic amino path,
then transported across the hepatocytes into the bile canali-
culi, and finally excreted through the bile ducts. Both scintig-
raphy and SPECT visualize the dynamic time course and thus
provide information regarding hepatic extraction and secre-
tion function.8 From the dynamic time–activity curve, hep-
atic extraction fraction (HEF) of 99mTc-IDA is estimated to
measure hepatic extraction function of the liver.3, 9 Using the
IDA agent of 99mTc-mebrofenin, HEF is close to 1 in nor-
mal subjects and patients with near normal liver functions.10
The decreases of HEF and the degree of HEF reduction are
directly proportionate to the severity of hepatocyte dysfunc-
tion on patients with hepatocyte diseases.9 However, due to
low spatial resolution and limited detail of the images, HEF
is usually quantified for the entire liver or regions of interest
(ROIs) in the liver.9–11 The lack of spatial discrimination in
the HEF hampers a wider range use of IDA imaging in clinic,
for examples, to assess regional hepatocyte dysfunction in the
course of a treatment.
Today’s technical advancements in hardware and software
of SPECT enable us to acquire a dynamic, volumetric hepato-
biliary SPECT with a spatial resolution of 3–4 mm,12 which
is significantly superior to the planar scintigraphy obtained
20 years ago. Moreover, the hybrid SPECT/CT system al-
lows acquisition of functional and anatomical images within a
single imaging session, and CT-based attenuation-correction
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for SPECT.13 In this study, using a hybrid SPECT/CT scan-
ner, we aim to evaluate the feasibility of quantifying HEF
on nontumor liver voxels from SPECT/CT with 99mTc-
mebrofenin, which may enable spatial assessment of hepatic
function.
To estimate the HEF from 99mTc-IDA images, a blood in-
put function should be determined. The heart, the most com-
mon region to determine blood input function for ROI-based
HEF quantification, may show large pulsation artifacts which
may compromise the reproducibility of voxelwise quantifica-
tion. With SPECT/CT, we were able to obtain blood input
function from a ROI delineated on the spleen. We therefore
compared the voxelwise HEF estimation from SPECT images
using arterial input function (AIF) from the heart with that
using vascular input function (VIF) from the spleen. To eval-
uate the spatially resolved HEF, we assessed the correlation
between mean of estimated HEFs in the liver and an inde-
pendent physiological measurement, i.e., Indocyanine green
(ICG) clearance rate. Blood clearance of ICG is an objec-
tive test of overall liver function, and has been routinely used
for planning of hepatectomy and liver transplantation.14–16
Therefore, this study will evaluate the potential of 99mTc-
IDA SPECT/CT to provide spatial assessment of hepatic
function.
2. MATERIALS AND METHODS
2.A. SPECT/CT
Fourteen patients (1 woman and 13 men, 44–83 years old)
with unresectable intrahepatic cancers participated in an in-
stitutional review board (IRB)-approved liver imaging study.
Nine patients had hepatocellular carcinoma (HCC), three had
cholangiocarcinoma, and the other two had metastases to the
liver. The patients were treated with 3D conformal RT (n
= 3, dose range: 50–64.8 Gy), intensity-modulated RT (n = 3,
dose range: 50–54 Gy), or stereotactic body RT (n = 8, dose
range: 17–50 Gy).
Dynamic SPECT of a patient was performed one week
prior to RT and one month after the completion of RT.
A Siemens hybrid SPECT/CT scanner (Symbia T6, Simens
Medical Solutions) was used. After 3–4 h fast, the pa-
tient received an intravenous injection of 10 mCi 99mTc-
mebrofenin. Dynamic data acquisition started immediately af-
ter the administration and lasted up to 60 min. The emission
data were acquired by using parallel-hole, high-resolution
collimators centered on the 140-keV photopeak with a 20%
symmetrical window. The acquisition was in 64 projections
(20 s per stop) with a noncircular orbit over 360◦ using a 128
× 128 matrix. A CT volume (matrix: 512 × 512 × 134; res-
olution: 1 × 1 × 2.5 mm3) was acquired immediately after
the dynamic SPECT with acquisition parameters of 130 kVp,
80 mAs, 0.8 pitch, and standard filters.
SPECT emission data were processed by using the filtered
backprojection method with CT-based attenuation correction.
A Butterworth filter with cutoff frequency of 0.2/cm was
applied. Twenty-seven SPECT volumes (matrix: 128 × 128
× 142; resolution: 3.9 × 3.9 × 2.5 mm3) were reconstructed,
in which the volumes 1–8, 9–14, 15–19, 20–21, 22–24, and
25–27 were with time intervals of 15 s, 30 s, 1 min, 2.5 min,
5 min, and 10 min, respectively. The time–activity curve of
each voxel was obtained by interpolating the 27 sampling
points to have a time interval of 15 s (Fig. 1).
2.B. ICG clearance test
The validity of HEF determination was evaluated by com-
paring to ICG clearance time (T1/2). ICG testing was per-
formed at ±1 day of each SPECT/CT scan. Two intravenous
catheters, one for ICG infusion and the other for drawing
blood samples, were used. Immediately after bolus adminis-
tration of ICG dye (0.5 mg/kg), blood samples (∼6 ml) were
drawn at time of 0, 5, 10, 15, and 20 min. The half-life time
(T1/2) of ICG clearance was determined by evaluating the
ICG concentration decay in the serum samples.17
2.C. Deconvolution analysis
Mathematically, a liver time–activity curve [l(t)] is yielded
from a convolution between a blood input function [b(t)] and
an impulse response function [h(t)] (Fig. 2):3
l(t) = b(t) ⊗ h(t), (1)
where t = nt (n = 0, 1, . . . , N − 1) is time sampling
a function with a time interval of t. With the knowledge
of the blood input and the liver time–activity curve, the im-
pulse response function can be estimated by deconvolution
computation.
















b(0) 0 . . . 0




























Medical Physics, Vol. 40, No. 9, September 2013
092501-3 H. Wang and Y. Cao: Hepatic function assessment 092501-3
FIG. 1. Color mapped SPECT overlapped on CT with ROIs drawn on the heart for an AIF (a) and on the spleen for a VIF (b). (c) Nontumor liver tissue
contoured on the liver and a tumor contoured by the circle. (d) Plots dynamic SPECT curves of a liver voxel, AIF from the heart and VIF from the spleen (b).
In order to solve the equation for H, square matrix B is de-
composed by singular value decomposition (SVD)
B = U · W · V T , (3)
where U and V are orthogonal, and W is diagonal with the el-
ements w0 ≥ w1 ≥ w2 ≥ · · · ≥ wN−1 ≥ 0. Then H is solved
as







· UT · L. (4)
Noise in the data will be magnified due to the inversion of
W if one or more wi values are zero or close to zero. The
truncated SVD method was used to resolve this problem, in
which a threshold c was defined and 1/wi was calculated only
for wi ≥ c. We heuristically determined c to ensure the HEFs
in normal liver tissue regions close to 100%. In this study, we
used 1% of the maximal singular value (w0) as c and 15 s for
the time interval t.
2.D. Hepatic extraction fraction estimation
The impulse response function [h(t)] resulting from the
SVD-based deconvolution describes the response of liver
parenchyma to a single bolus of IDA agent injected directly
into the hepatic vasculature without subsequent recirculation.
Because of the time delay for blood input bolus reaching the
liver parenchyma, the impulse response function began with
a sharp increase and then divided into the vascular phase and
the hepatocyte retention phase (Fig. 2).3 Following the con-
ventional approach,3, 10 we fitted the retention phase in h(t)
with an exponential function, and then extrapolated the expo-
nential function back to the initial time of the hepatocyte re-
tention when the activity of the vascular phase was maximal.
Finally, HEF was computed as the ratio between the fitted ac-
tivity at the initial time of the hepatocyte retention and the
peak activity of the vascular phase:
HEF = fitted initial hepatocyte retention
peak of vascular phase
. (5)
Least squares minimization was performed for the expo-
nential fitting of the retention phase in the impulse response
FIG. 2. Impulse response function from deconvolution for HEF estimation.
The deconvolution was done between a SPECT curve of a liver voxel and the
VIF from the spleen. Time course of 7–30 min was defined as the retention
phase of the impulse response function. Exponential fitting of the retention
phase is shown and extrapolated to initial time of the retention when the vas-
cular phase was maximal.
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function. The time range for the retention phase needs to be
specified before the fitting. It is generally accepted that the
secretion of IDA becomes dominant approximately 30 min
after injection,10 and a number of studies defined the reten-
tion phase between 6 and 30 min after the injection of IDA
agent.3, 10 For the patients with intrahepatic cancers, we ex-
amined time ranges of 6–30 min (T6-30), 7–30 min (T7-30),
and 8–30 min (T8-30) for the retention phase to determine
the impact of the time range parameter on voxelwise HEF
quantification.
Normal liver parenchyma extracts 95%–100% of 99mTc-
mebrofenin in incoming blood, and thus the HEF is close to
1.10 Hepatocytes in damaged liver tissue are only able to re-
tain a small portion of the total IDA agent, indicating a HEF
less than 1. Therefore, the HEF is supposed to be bounded
between 0 and 1. However, due to image noise and artifacts,
the voxelwise HEF may be beyond the range, particularly,
at the voxels in normal liver parenchyma. In this study, we
also calculated the percentage of voxels whose HEFs were
within the range in order to evaluate the reliability of the HEF
estimation.
2.E. Input function determination and image analysis
The blood input function b(t) in the deconvolution anal-
ysis was obtained from a ROI on the heart in most 99mTc-
IDA scintigraphy studies of hepatocellular function.3, 4, 6, 9, 11
In this SPECT/CT study, we compared the voxelwise HEF
estimation using AIF from the heart with the estimation us-
ing VIF from the spleen. On the axial CT of the SPECT/CT,
ROIs were delineated on the left ventricle of the heart and the
spleen. In order to minimize spillover and partial-volume ef-
fects in SPECT, the ROI on the heart was placed at least 2 pix-
els away from the heart wall, and the ROI on the spleen was
also at least 2 pixels away from the boundary of the spleen.
We selected the SPECT volume that had peak activity on the
time–activity curve for the heart ROIs, and then iteratively
used a stepwise threshold to remove low SPECT activity until
the ROI had approximate 100 voxels. Similarly, we generated
a ROI with 100–200 voxels on the spleen. The AIF and the
VIF were the time–activity curves of mean activity on respec-
tive ROI. Figure 1 shows the ROIs on the heart [Fig. 1(a)] and
the spleen [Fig. 1(b)] from which the AIF and the VIF were
generated [Fig. 1(c)].
The liver was delineated on the CT of the SPECT/CT. To
mitigate partial volume effect on the HEF estimation, 2 pix-
els from the delineated boundary of the liver were excluded
by morphological erosion on each image plane. Care was also
taken to exclude major blood vessels, visible bile ducts, and
gallbladder from the liver. The HEFs of the liver before and
one month after RT were estimated voxel-by-voxel using the
AIF and the VIF, as well as the three time ranges for the re-
tention phase (T6-30, T7-30, and T8-30). To evaluate the re-
liability of the voxelwise HEF estimation, a ROI was drawn
on the nontumor liver region with relatively homogenous tis-
sue. The ROI was placed far away from tumors and with the
planned radiation dose less than 10 Gy that seems to have
minimal effect in the liver.18
2.F. Statistical analysis
Descriptive statistics [mean, standard deviation (std), me-
dian, maximum, and minimum] was calculated for the HEFs
in each ROI with respect to the use of the AIF or the VIF
and the time ranges for the retention phase. The means of the
HEFs in the ROIs were compared between using the AIF and
the VIF by paired t-test. The test was also performed between
the time ranges for the retention phase. To evaluate the un-
certainty of the voxelwise HEF estimation, we calculated the
relative variation of the HEFs in the ROIs, which was cal-
culated as the ratio of standard deviation to the mean of the
HEFs.
Mean of the HEFs over a whole liver excluding gross tu-
mor volumes [Fig. 1(c)] was calculated. Any HEF above 1
was set as 1 in the mean HEF calculation. We evaluated the
correlation between mean of the HEFs over the liver and the
ICG clearance half-time T1/2 by Spearman’s rank correla-
tion coefficient (r) on all imaging sessions. ICG clearance
test is clinically used to measure overall liver function, there-
fore the correlation between the mean of the HEFs over the
liver and the T1/2 verified the voxelwise HEFs as measure of
liver function. The statistical package of R was used,19 and a
two-sided p-value less than 0.05 was considered statistically
significant.
3. RESULTS
Means of the HEFs in the drawn ROIs for all imaging ses-
sions were compared with respect to the AIF from the heart
and the VIF from the spleen (Fig. 3). The ROIs have a size of
1845 ± 659 voxels. As the ROIs were drawn away from the
tumors, the median HEF is around 0.8 when computing with
the AIF and is around 0.7 if using the VIF, regardless of the
given time ranges for the retention phase. The t-test (Table I)
shows significant difference in the mean HEFs of the ROIs
between using the AIF and the VIF (p < 0.0001). However,
using either the AIF or the VIF, there is no significant differ-
ence in the mean ROI HEFs between the three time ranges
FIG. 3. Distribution of means of HEFs in the ROIs of the patients estimated
with AIF from the heart and VIF from the spleen. The ROIs (∼1845 voxels)
were drawn on the liver tissue far away from the tumor and receiving radiation
dose less than 10 Gy.
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TABLE I. Paired t-test for means of HEFs in the ROIs.
T6-30 T7-30 T8-30
AIF VIF AIF VIF AIF VIF
Mean 0.83 0.71 0.83 0.71 0.82 0.70
Standard deviation 0.12 0.16 0.11 0.16 0.13 0.18
t-test between using AIF and VIF (p-value) 1.09 × 10−6 3.55 × 10−6 1.38 × 10−5
T6-30 T7-30 T7-30 T8-30 T6-30 T8-30
t-test between time ranges with using AIF (p-value) 0.06 0.47 0.52
t-test between time ranges with using VIF (p-value) 0.39 0.1 0.23
for the retention phase (p > 0.05), suggesting that the HEF
estimation is relatively robust to the selection of time range
for the retention phase.
The correlation for a total of 28 pairs of means of liver
HEFs and ICG clearance T1/2 is shown in Fig. 4. The HEFs
were estimated with the time range of 7–30 min for the
retention phase. Although the means of the live HEFs es-
timated with the AIF and the VIF both are significantly
correlated with the T1/2 (p = 0.0004 for the AIF, and p
< 0.0001 for the VIF), the correlation of the mean of HEFs
estimated with the VIF is much better (r = 0.79) than us-
ing the AIF (r = 0.52). The correlations indicate that the
voxelwise HEF derived from 99mTc-mebrofenin SPECT us-
ing VIF is able to assess hepatic function. Using the VIF
and the retention phase time ranges of 6–30 and 8–30 min,
the Spearman’s correlation coefficients between the mean of
the HEFs over the liver and the T1/2 are 0.78 and 0.76, re-
spectively, indicating the robustness of the HEF estimation
to the time range parameter. Based on the correlation coeffi-
cients, VIF and the retention phase time range 7–30 min could
be used to estimate the HEF voxel-by-voxel from 99mTc-
mebrofenin SPECT for evaluating spatially resolved hepatic
function.
FIG. 4. Correlation between ICG T1/2 and mean of HEFs over the nontumor
liver tissue estimated using the AIF in the heart and the VIF from the spleen.
The retention phase was set as 7–30 min.
We next evaluated the variation of the HEF estimated with
the VIF. Figure 5 compares the relative variations of the vox-
elwise HEF in the drawn ROIs among the three time range
settings. In the ROIs, there are no significant differences in the
HEF relative variations for any paired time ranges of the re-
tention phase (p > 0.4). The range of the relative variation of
the HEFs in the ROIs estimated with T7-30 (mean: 10%; std:
6%) is 5%–25% that is smaller than the ranges of 5%–54%
and 4%–33% for the HEFs estimated with T6-30 and T8-30,
respectively. Considering the relative variation of SPECT in-
tensities in these ROIs with a mean value of 15% (std: 6%),
the variation of the HEF estimated with a VIF and T7-30 indi-
cates the feasibility of the HIDA SPECT-derived HEF for spa-
tial quantification of liver function. The percentage of voxels
with a HEF not greater than 1 was calculated for each imag-
ing session. In all the tumor-excluded livers (volume: 1092
± 460 cm3), 89% ± 7% of the volume has voxelwise HEFs
not greater than 1, suggesting the reliability of the HEF quan-
tification to some extent.
Parametric maps of the HEF in the liver before and one
month after RT for one patient are shown in Fig. 6. The
HEF was estimated with VIF and the retention phase of 7–
30 min after the injection of 99mTc-mebrofenin. Radiation
therapy led to reduction of the HEF one month after the treat-
ment, and the amplitude of reduction seems greater at the
region close to the planning target volume (marked circles)
where the highest radiation dose was delivered to treat the
cholangiocarcinoma.
FIG. 5. Relative variations of HEFs in the ROIs estimated using the VIF and
different time ranges for the retention phase.
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FIG. 6. HEF maps overlapped on treatment planning CT. Left are slices of the treatment planning CT, middle and the right are color mapped HEFs before and
1 month after RT, respectively, overlapped on the CT. The HEF was estimated voxel-by-voxel using the VIF and 7–30 min for the retention phase. Any HEF
above 1 is displayed as 1. Planning target regions (PTV) that received highest radiation dose are shown as the circles on the right figures.
4. DISCUSSION
In this study, the performance of the voxelwise HEF es-
timation was evaluated with respect to the blood input func-
tions from the heart and the spleen, as well as the parameter
of time range for the retention phase. The mean of the HEFs
over the liver estimated with the VIF from the spleen shows a
much more significant correlation with the overall liver func-
tion compared with the mean of HEFs estimated with the AIF
from the heart. In contrast to the 99mTc-IDA scintigraphic
studies of hepatic function in whole organ or ROI level, the
study demonstrates the feasibility of 99mTc-IDA SPECT to
spatially assess hepatic function of the patients with intrahep-
atic cancers.
Our study estimated the HEF voxel-by-voxel from 99mTc-
mebrofenin SPECT acquired on a hybrid SPECT/CT scanner
to assess hepatic function with spatial distribution. The HEF
was evaluated in the ROIs that were placed to have hepatic
function as homogeneous as possible. Our results show the
estimation is rather insensitive to the parameter of time range
for the retention phase regardless using the AIF from the heart
or the VIF from the spleen. Furthermore, we show that the
volumetric-weighted mean HEF of the liver significantly cor-
relates with the global liver function measured by the ICG
clearance test, and the correlation using the VIF is much bet-
ter than the correlation using the AIF. The correlation is ro-
bust for the patients with primary or metastatic liver can-
cers and having a wide range of liver functions (T1/2: 4.25–
14.64 min). Currently, liver function is most often assessed by
serum analyte measurements or scoring based on clearance
tests.14 These tests can assess the overall liver function, but
cannot investigate hepatic function in a regional or segmental
manner. Therefore, the volumetric HEF derived from 99mTc-
IDA SPECT provides complementary spatial information for
the global hepatic function.
The knowledge of IDA blood input function is required
for HEF estimation. Previously, the input function was usu-
ally obtained from a ROI on the heart as the planar scintig-
raphy did not have detailed anatomical information. In this
study, with an anatomical CT of SPECT/CT, we have shown
that the VIF from the spleen achieved better correlation be-
tween the mean of HEFs over the liver and the overall liver
function measured by the ICG clearance test. The results
suggest that the bolus passage of IDA agents in the spleen
vessels may be more representative of the bolus in the cap-
illaries of the liver. The liver has dual blood inputs from the
portal vein and the hepatic artery. While the majority of blood
supply to liver tumor is from the hepatic artery, normal liver
tissue derives approximately 85% of its blood supply from
the portal vein.20 Therefore, for nontumor liver tissue evalu-
ated for hepatic function, the VIF from a ROI on the spleen
that is composed of both artery and vein voxels may bet-
ter indicate the dynamic of the tracer input to the liver than
the AIF from the heart. To assess hepatic extraction using
hepatocyte-specific contrast-enhanced MRI in healthy volun-
teers, the VIF directly obtained from the pixels in the portal
vein was used by others.21 Due to the difficulty of identify-
ing the portal vein in SPECT/CT, we believe that the input
function from the spleen is a valid choice for the HEF quan-
tification from 99mTc-IDA SPECT, particularly, to assess
treatment-induced liver damage in which the hepatic function
in the nontumor liver tissue is mostly considered. This study
estimated HEF from dynamic SPECT images without scatter
correction. For 99mTc SPECT images, the ratio of scattered
to primary photons in the photopeak energy window could
be as high as about 30%. However, The HEF is calculated
as a ratio derived from the impulse response function, which
only depends on the shape of the dynamic curve at a voxel.
Therefore, scatter may have less effect on the voxelwise HEF
quantification.
Increasing radiation dose for better radiation therapy of
liver cancer is limited by the development of radiation-
induced liver disease.22 Likewise, the major cause for postop-
erative mortality after liver surgery is the liver failure.23 This
study shows the potential of 99mTc-IDA SPECT to depict
hepatic function in a voxel or regional level. The spatially
resolved imaging of liver function could be used to investi-
gate treatment toxicity in the liver and certainly be of great
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value in treatment planning for radiation therapy or resection
of liver cancer, by which the normally functioning liver re-
gions can be preserved to minimize liver injury while poorly
functioning liver segments can be sacrificed for optimal tu-
mor ablation. Furthermore, assessing liver function response
to therapy by 99mTc-IDA SPECT may enable prediction
of treatment-induced liver complication, and thereby reopti-
mize treatment planning for liver cancer during the therapy.
Further studies are required to assess the reproducibility of the
voxelwise HEF quantification, and to evaluate the relationship
between the regional HEF change and the applied treatment.
In this examination of 99mTc-mebrofenin SPECT for assess-
ment of hepatic function response to therapy, we focused on
evaluating the HEF in the nontumor liver voxels. The poten-
tial of HEF quantification and 99mTc-IDA SPECT to assess
residual hepatic function in liver cancer may be investigated
in the future.
5. CONCLUSIONS
Spatially resolved hepatic function in the liver can be eval-
uated by using the voxelwise HEF derived from 99mTc-IDA
SPECT. By the deconvolution analysis with a vascular in-
put function from the spleen, the mean HEF of the liver cor-
related with the overall liver function assessed by an inde-
pendent physiological measurement. 99mTc-IDA SPECT and
the voxelwise HEF may provide a tool to assess liver func-
tion response to therapy to minimize treatment-induced liver
dysfunction.
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